Insights From Technical Analysis
New Murchison Gold (ASX: NMG): Pay for the Current Gold, Get the Exploration Potential for Free
New Murchison Gold Limited is a small Australian gold producer operating the Crown Prince mine in Western Australia. The company recently transitioned from exploration to production and is generating strong cash flow from high-grade ore sold to Westgold Resources Limited. Exploration at nearby targets and potential underground mining could extend the project’s life and add future growth potential.
Electro Optic Systems (ASX: EOS): Pricing the Counter-Drone and Laser Defence Opportunity
Electro Optic Systems develops remote weapon systems, counter-drone platforms and laser defence technologies for military customers. Despite strong order-book growth and rising defence demand, the company still generates operating losses and negative cash flow. Its valuation is largely based on future growth in counter-drone and directed-energy defence systems.
Racura Oncology Ltd (ASX: RAC): Could RC220 Turn This Small Biotech into a Billion-Dollar Cancer Stock?
Racura Oncology is a clinical-stage biotech developing RC220 (bisantrene), a potential treatment for cancers such as AML and lung cancer. The company is pre-revenue and mainly funded through cash reserves and capital raises while advancing clinical trials. Its future valuation depends largely on trial results, regulatory progress and potential partnerships if the drug proves effective.
Has Telix Pharmaceutical's (ASX: TLX) share price reached the bottom?
Telix Pharmaceuticals is a radiopharmaceutical company focused on cancer imaging and therapies, with strong revenue growth driven by products like Illuccix and Gozellix. While recent gains suggest the stock may be stabilising, future performance will depend on continued commercial growth and pipeline progress.
How much higher can Lynas Rare Earths (ASX: LYC) share price go?
Lynas Rare Earths is the largest rare earth producer outside China, supplying critical magnet materials used in EVs, renewable energy and defence technologies. Its core Mt Weld mine and expanding processing facilities position the company as a key player in the Western rare earth supply chain. While earnings remain highly sensitive to rare earth prices, ongoing capacity expansion and stronger NdPr demand could support significant long-term growth.
Mineral Resources (ASX: MIN): An undervalued ASX miner facing an important resistance level
Mineral Resources is emerging from a heavy investment phase as the Onslow Iron project reaches scale, driving a sharp recovery in earnings and cash flow. With iron ore production ramped up and lithium assets backed by a major POSCO partnership, the business is now showing the financial benefits of years of expansion. Despite the turnaround, the stock still appears undervalued relative to its long‑term earnings, cash‑flow potential, and asset base.
TechnologyOne (ASX: TNE): A Defensive SaaS Compounder with Premium Valuation
TechnologyOne is a leading Australian SaaS provider delivering cloud ERP software to governments and large organisations. Its recurring revenue model supports strong margins and steady growth. However, the stock trades at a premium valuation, leaving little margin for growth disappointments.
Paladin Energy (ASX: PDN): A Leveraged Play on the Uranium Price Recovery
Paladin Energy is a leveraged uranium producer centred on the restarted Langer Heinrich mine in Namibia. Its earnings are highly sensitive to uranium prices, making the stock a direct play on the nuclear fuel cycle. Future growth could come from the large Patterson Lake South project in Canada.
Immutep (ASX: IMM): A High-Risk Immunotherapy Bet Waiting for Phase III Validation
Immutep is a Sydney-based clinical-stage biotechnology company focused on immunotherapy, specifically targeting the LAG-3 immune pathway. The company is dual-listed on the ASX and NASDAQ, giving it access to both Australian and US capital markets. It does not yet generate commercial product revenue and remains dependent on capital markets and partnerships to fund its development programs, making it a milestone-driven investment rather than a revenue-backed operating business.
Has Neuren Pharmaceuticals' (NEU) share price bottomed out?
If you bought Neuren Pharmaceuticals (ASX: NEU) near its peak, the recent volatility has been uncomfortable. Despite having its first approved drug for a rare paediatric disorder, growing royalty income and a promising pipeline, the share price has repeatedly rallied and retraced over the past two years. The key question now is whether NEU has already formed a durable bottom — or if another leg down could still test investor conviction.
WiseTech Global (ASX: WTC) – Testing the $2bn Strategic Gamble
WiseTech Global’s A$2bn acquisition of E2open has significantly boosted revenue but diluted margins and increased leverage, shifting the investment case from premium organic growth to execution-driven integration. While the long-term strategic rationale remains sound, near-term earnings pressure and higher balance sheet risk make valuation more demanding and leave little room for integration missteps.
Has PolyNovo's (ASX: PNV) share price hit the bottom yet?
PolyNovo Limited (ASX: PNV) remains a fundamentally strong, high-growth medtech, but its share price is currently testing key support around A$0.88–0.92 within a broader sideways range. While selling pressure has eased and momentum is stabilising, a confirmed bottom would require a sustained break above A$1.08; otherwise, a fall below A$0.86–0.90 could signal further downside.
Silver’s On the Move Again: Is Investigator Silver (IVR) Worth Another Look?
Silver has rebounded sharply after a brutal 30–40% pullback, driven by geopolitical tensions and renewed macro uncertainty. Against this backdrop, Investigator Resources Ltd (ASX: IVR) — whose share price has more than tripled over the past year — has pulled back from recent highs as traders de-risk. The key question now is whether silver’s renewed surge signals another leg higher, offering leveraged upside for IVR, or just more short-term volatility.
How much lower could Hot Chili’s (ASX: HCH) recently started downtrend take the share price?
Hot Chili Limited is a pre-revenue copper developer focused on its large-scale Costa Fuego project in Chile, supported by strategic water infrastructure and long-term exposure to the global copper supply deficit theme. However, its recent share price weakness has been driven by a discounted capital raising, ongoing dilution risk, high cash burn, valuation concerns, and broader copper-sector volatility. Technically, the stock has entered a correction phase, with downside support levels around A$1.25–1.30, A$1.15 and near A$1.00, while a sustained break below the A$0.80–0.90 zone would signal a deeper trend reversal.
Most lithium explorers are falling — why is Atlantic Lithium (ASX: A11) holding up, and what does it signal?
Atlantic Lithium is holding up while many lithium explorers fall because it is further advanced toward production, with permitting progress at Ewoyaa, funding support, and improving lithium prices underpinning confidence. Strong drilling results and a clear path to FID differentiate it from early-stage peers. Technically, the stock remains in an uptrend with solid volume support, signalling accumulation rather than distribution and suggesting investors are backing execution, not just sentiment.
How much should we be scared of the recent gap down in CSL's (ASX: CSL) share price?
CSL Limited’s recent gap down reflects a sharp reset in market confidence rather than a collapse in its core business. The fall was driven by weaker-than-expected H1 FY26 results, plasma division margin pressure, policy headwinds in the US and China, a surprise CEO change, and earlier guidance cuts. While the stock is technically in a clear downtrend and deeply oversold, the long-term investment case now hinges on execution, margin recovery, and whether management can rebuild credibility.
Brainchip Holding's (ASX: BRN) downtrend is in full force. How much lower can it go?
Brainchip Holdings (ASX: BRN) is in a clear downtrend, with persistent selling pressure keeping it near lows and preventing sustained gains, as weak technicals and broader tech sector headwinds continue to weigh on the stock.
Atlantic Lithium’s (ASX: A11) uptrend is holding amid heavy market turbulence. How significant is this show of resilience?
Atlantic Lithium has managed to hold its uptrend despite broader market turbulence, a sign of underlying strength in a weak environment for resource stocks. Steady buying at key support levels suggests confidence has not collapsed, supported by progress at its Ewoyaa lithium project in Ghana. This combination of solid fundamentals and constructive chart behaviour highlights resilience in a volatile, sentiment-driven sector.
European Lithium's (ASX: EUR) share price has bounced off its support level nicely. How much higher can it go?
European Lithium (ASX: EUR) has rebounded from a well-established support level on its daily chart, a move that suggests buyers continue to defend this key zone. While the company’s Wolfsberg project underpins its long-term European battery supply narrative, the recent lift is largely technical, driven by market psychology and historical buying interest.
Appen (ASX: APX) - One of the few AI stocks on the ASX with a currently rising share price
Appen Limited (ASX: APX), founded in 1996 and listed since 2015, is an Australian AI data specialist providing dataset sourcing, annotation, and model evaluation. Operating the Global Services and New Markets segments, it serves major tech clients across multiple industries, leveraging a 1M+ global workforce that spans 180+ languages in 130 countries.
Arafura Rare Earths's (ASX: ARU) share price is trading at a strong support level, is it a buying opportunity?
Arafura Rare Earths (ASX: ARU) is trading near a key support zone after recent volatility, where buyers have previously stepped in. Strength in rare earth prices adds sector momentum. While this mix may signal opportunity, confirmation depends on support holding and the company delivering meaningful project progress.
Atomo Diagnostics (ASX: AT1) uptrend is your friend!
Atomo Diagnostics (ASX: AT1) is showing a steady uptrend after a long quiet phase. Rising prices from recent lows, backed by stronger volume, suggest buyers are gradually absorbing supply. This persistent move higher points to improving sentiment and a technically supportive trend for now.
Waratah Mineral (ASX: WTM) has made multiple higher lows. Is it building the base for another leg up?
Waratah Minerals, an Australian gold-copper explorer in NSW, has rebounded strongly from last year’s lows. A clear pattern of higher lows suggests growing accumulation, easing selling pressure and sustained market interest, positioning the stock to potentially break higher if a catalyst emerges.
Why is SportsHero's (ASX: SHO) share price rising and how much higher can it go?
SportsHero (ASX: SHO) is an early-stage Australian sports gamification and media company focused on mobile-first prediction and gaming platforms across Southeast Asia, primarily Indonesia. It offers leveraged exposure to regional digital gaming growth but carries high execution, funding and profitability risk typical of small-cap platform build-outs.
.webp&w=828&q=75)
How much higher can Korvest (ASX: KOV) share price go after the recent breakout?
Korvest Ltd (ASX: KOV) is a South Australian industrial manufacturer specialising in cable and pipe support systems and corrosion protection services, with earnings linked to infrastructure, resources, energy and industrial activity, as well as ongoing maintenance demand.
Xero Limited (ASX: XRO): From Accounting Software to Global Small Business Operating System
Xero is transitioning from a high-growth SaaS accounting platform into a global small business operating system with improving earnings quality and rising operating leverage. FY26 interim results show resilient revenue growth, margin expansion from cost discipline, and deeper monetisation across payments, payroll and financial services. We believe the market still applies an outdated growth-at-any-cost lens, underestimating Xero’s emerging cash generation and embedded optionality.
Megaport Limited (ASX: MP1), Re-Establishing Structural Growth Leverage
Megaport has evolved from a cash-intensive growth story into a more disciplined, cash-generative digital infrastructure business, with FY25 marking a clear structural turning point as costs reset, churn stabilised and balance-sheet risk reduced. While the market still views the company through outdated perceptions, we see improved unit economics, renewed credibility and emerging operating leverage, positioning Megaport for growing free cash flow and ongoing relevance in an increasingly hybrid, multi-cloud world.
These ASX stocks have recently had major share price breakouts
When a share price breaks out after a long period of consolidation, it often signals a meaningful shift in market sentiment, marked by rising volume, improving momentum and former resistance turning into support. In recent weeks, several ASX stocks have shown these clean, technically supported breakouts, suggesting these are not short-lived spikes but structured moves that technical analysts closely watch as potential early signs of a new trend.
3 ASX stocks with confirmed bullish divergence patterns
The Australian share market has a habit of sending quiet signals before a move actually happens. One of the most reliable of those signals is bullish divergence, a moment when price looks weak, but momentum quietly starts to improve. In this article, we’ll take a closer look at three stocks listed on the (ASX) that are currently showing confirmed bullish divergence patterns.
3 ASX Stocks on Solid Share Price Uptrends
Every so often, the market serves up a handful of charts that practically nudge you to take a closer look. You know the type, steady higher lows, clean breakouts, and that subtle shift in momentum that hints at a story unfolding beneath the surface. In this piece, we’re turning the spotlight on three ASX-listed stocks whose price action has been speaking in a clear and confident tone. These aren’t wild speculative swings or one-off spikes; they’re structured uptrends that have earned their place on watchlists through consistent behaviour.
CSL Limited (ASX: CSL) – Structural Quality Re-Asserted
We believe CSL Limited (ASX: CSL) remains one of the highest-quality global healthcare franchises listed on the ASX, with FY25 marking a clear re-acceleration in earnings quality, cash flow conversion, and strategic clarity. While the share price has periodically struggled to reflect this underlying strength, we view CSL as misunderstood rather than mis-executing.
LaserBond (ASX: LBL)- Engineered for Investors Seeking Durable Industrial Growth Exposure
LaserBond (ASX: LBL) has entered a structurally stronger period after FY25 delivered clear evidence of operating leverage, improved manufacturing efficiencies, and accelerating adoption of its surface-engineered technologies across mining, energy, defence, and agricultural markets. With its patented LaserBond® cladding and composite coating systems now demonstrating superior lifecycle economics versus traditional wear-resistance methods, the company is positioned as a high-margin engineering solutions provider rather than a cyclical industrial.
Sunrise Energy Metals (ASX: SRL) - Positioned at the Strategic Heart of Western Critical Minerals Supply Chains
Sunrise Energy Metals (ASX: SRL) is advancing one of the Western world’s most strategically significant battery-materials developments: the Sunrise Nickel-Cobalt-Scandium Project in NSW, a globally large, long-life, ESG-aligned source of critical minerals essential for EVs, aerospace alloys, defence technologies and high-performance fuel cells. Backed by strong balance sheet discipline, rising government engagement, escalating Western supply-security policies, and material advancement across strategic partnerships during 2025, Sunrise enters 2026 with a profile we view as deeply undervalued relative to its strategic optionality.
How Much Higher Can Recce Pharmaceuticals' (ASX: RCE) Share Price Go After the Recent Breakout?
Recce has recently attracted attention because it’s advancing drug candidates against serious infections, a space with significant potential if late-stage trials succeed. That kind of promise is why some market watchers see upside in RCE’s shares. On the flip side, the company remains unprofitable, with no consistent earnings or predictable cash flow, so it’s still a speculative biotech rather than a stable performer.
How Much Higher Can CETTIRE's (ASX: CTT) Share Price Go After the Recent Breakout?
Cettire (ASX: CTT) share price recently had a breakout. But it is in a bit of limbo; enough promise remains that a rebound could be on the cards, but enough uncertainty that it’s far from a safe bet. On one hand, the company is forecast to post healthy earnings-per-share growth over the next few years and has a pretty low price-to-sales ratio compared with peers, suggesting some latent value. On the other hand, consensus analyst targets hover modestly, some even see a drop, and many believe any upside beyond roughly one Australian dollar a share depends on improvements that aren’t guaranteed.
Control Bionics (ASX: CBL) - This microcap's share price could explode higher from here!
The small-cap medical-tech company, Control Bionics, has just taken steps that could catapult it far beyond its current size. Its core product, a wearable sensor that translates even the faintest muscle or nerve signals into computer commands, is already approved and helps people with severe physical disabilities communicate and interact. Recently, the company announced that it had integrated a significant tech giant’s brain-computer interface protocol into its devices.
Investigator Silver (ASX: IVR)- Positions for Catalysts Amid Strengthening Silver Market
Investigator Silver (ASX: IVR), formerly known as Investigator Resources, is moving through one of the most strategically important phases in its history. The company is advancing the Paris Silver Project, Australia’s highest-grade undeveloped primary silver deposit, while simultaneously delivering exploration wins across its 100%-owned Peterlumbo tenement and progressing copper-gold targets at Uno Morgans.
3 ASX Stocks with Bullish Charts
When you spend enough time around the ASX, you start to notice a certain rhythm in how strong charts behave. Some stocks creep for weeks, building energy in tight ranges, and then, almost without announcement, they begin flashing early signs of strength. In this review, we focus on three ASX-listed companies whose price action suggests further upside.
3 ASX Stocks with Recent Bullish Breakouts
When you track the ASX day after day, you eventually spot those moments when a stock stops drifting and suddenly kicks into gear. A clear breakout, the kind that pushes past weeks of hesitation, often tells you buyers are finally taking control. In this article, we’re looking at three Australian companies whose share prices have recently surged through key resistance levels. These aren’t just quick spikes or one-day wonders. Each chart shows a pattern of tightening ranges, rising volume, and a decisive move that suggests momentum may continue.
Zip Co Limited (ASX: ZIP) — From BNPL Pioneer to Global Fintech Contender
Zip closed FY25 with what we consider a genuine inflection point: a record A$13.1bn in TTV and A$170.3m of group cash EBTDA — a level of profitability that would’ve sounded fanciful 18 months ago. The US arm is now the locomotive of the group, while ANZ has quietly rebuilt its margin spine. Momentum spilled straight into 1Q FY26, with TTV of A$3.9bn and cash EBTDA of A$62.8m, prompting management to hike US TTV guidance and expand the buyback to A$100m.
Invictus Energy (ASX: IVZ) – A Frontier Play with Optionality
We view Invictus Energy as a rare example of an explorer with a clear pathway to development in one of Africa’s last underexplored rift systems. The Mukuyu gas-condensate discovery in Zimbabwe’s Cabora Bassa Basin anchors the portfolio, while high-impact follow-up at Musuma-1 and a strategic financing partnership with Al Mansour Holdings (AMH) materially de-risk the next stage of value creation.
3 ASX Stocks with Bearish Charts, Which Can Go Much Lower!
In the current markets, even major players listed on the S&P/ASX 200 aren’t immune to caution flags on the charts. In this article, we'll examine three ASX-listed stocks whose price action suggests further downside may be ahead. We’ll look beyond the fundamentals and focus on technical signals: breakdowns below key moving averages, chart patterns like lower highs or descending triangles, and weakening momentum indicators.
BrainChip Holdings (ASX: BRN): High-Optionality Growth Play
BrainChip is a pioneer in ultra-low-power, neuromorphic AI processing, anchored by its Akida spiking neural network architecture. With US$13.5 million cash as of June 2025, the company is funding aggressive commercialisation efforts, including next-gen Akida 2.0, Pico devices, and defence / edge-AI partnerships. While financial performance is still pre-profit, recent commercial wins, deep IP protection, and product roadmap momentum provide compelling optional upside. Key risks include cash burn, technology adoption, and scaling edge-AI deployments.
European Lithium (ASX: EUR) — the Push toward European Lithium Independence
European Lithium is positioning itself as a future supplier of battery-grade lithium to Europe, with the Wolfsberg Project in Austria advancing through permitting, engineering, and early-stage financing activities.
Racura Oncology (ASX: RAC) - A High-Risk, High-Reward Oncology Play
Racura Oncology (ASX: RAC) is executing on a bold clinical strategy centered on RC220 (bisantrene reformulation), targeting both cardioprotection and enhanced anticancer activity in combination with doxorubicin. The company has dosed its first patient in a Phase 1 solid tumor trial, expanded into South Korea, and strengthened its clinical leadership team, all while maintaining disciplined cash management (A$13.67m at June 2025) to fund operations into 2026. Though early-stage, RAC presents a compelling mid- to long-term optionality scenario for investors with conviction in cardio-oncology and specialty chemotherapy.
Arafura Rare Earths (ASX: ARU) — Building Australia’s Rare Earth Future
Arafura Rare Earths (ARU) is progressing its flagship Nolans NdPr Project in the Northern Territory — a fully integrated mine-to-separation operation targeting strategic electrification supply chains. With formal government backing, advanced engineering progress, and off-take partnerships in motion, ARU is positioning itself as a critical rare-earth supplier to global EV and wind OEMs.
Talga Group (ASX: TLG) — Powering Europe’s Low-Carbon Battery Future
Talga Group is positioning itself as a cornerstone of Europe’s sustainable battery supply chain through its integrated mine-to-anode model in Sweden. With its Luleå anode refinery approaching production readiness and government-backed funding in place, Talga is moving from concept to commercial reality. The company’s low-carbon Talnode® products target the fast-growing EV and energy-storage markets, offering a differentiated, locally sourced alternative to Asian graphite imports.
Larvotto Resources (ASX: LRV): Building Australia’s Next Antimony–Gold Producer
Larvotto Resources Limited (ASX: LRV) is an Australian emerging mining company transitioning from explorer to near-term producer. Its flagship asset, the Hillgrove Antimony–Gold Project in New South Wales, positions the company as a potential supplier of two strategically important metals: gold—a monetary safe-haven—and antimony, a critical mineral used in batteries, semiconductors, and defense alloys.
Liontown Resources (ASX: LTR): Powering the EV Revolution from Kathleen Valley
Liontown Resources (ASX: LTR) is a next-generation lithium developer advancing toward production at its flagship Kathleen Valley Project in Western Australia. With Tier-1 offtake partners and strong financial backing, Liontown is poised to become a key player in the global EV and battery supply chain.